IN2012DN04908A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN04908A IN2012DN04908A IN4908DEN2012A IN2012DN04908A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A IN 4908DEN2012 A IN4908DEN2012 A IN 4908DEN2012A IN 2012DN04908 A IN2012DN04908 A IN 2012DN04908A
- Authority
- IN
- India
- Prior art keywords
- antibody
- disclosed
- antibodies
- expressing cells
- drug conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28501809P | 2009-12-09 | 2009-12-09 | |
PCT/IB2010/003411 WO2011070443A1 (en) | 2009-12-09 | 2010-12-08 | Monoclonal antibodies that bind b7h6 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN04908A true IN2012DN04908A (es) | 2015-09-25 |
Family
ID=43827827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN4908DEN2012 IN2012DN04908A (es) | 2009-12-09 | 2010-12-08 |
Country Status (18)
Country | Link |
---|---|
US (2) | US8822652B2 (es) |
EP (1) | EP2510011B2 (es) |
JP (2) | JP2013513380A (es) |
CN (2) | CN104926942B (es) |
BR (1) | BR112012013975B8 (es) |
CA (1) | CA2783740C (es) |
DK (1) | DK2510011T3 (es) |
EA (1) | EA024629B1 (es) |
ES (1) | ES2523472T3 (es) |
HR (1) | HRP20141170T1 (es) |
IN (1) | IN2012DN04908A (es) |
MX (1) | MX2012006443A (es) |
PL (1) | PL2510011T3 (es) |
PT (1) | PT2510011E (es) |
RS (1) | RS53667B1 (es) |
SI (1) | SI2510011T1 (es) |
SM (1) | SMT201400184B (es) |
WO (1) | WO2011070443A1 (es) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
MX2012006443A (es) | 2009-12-09 | 2012-06-28 | Inst Nat Sante Rech Med | Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos. |
WO2013033626A2 (en) | 2011-08-31 | 2013-03-07 | Trustees Of Dartmouth College | Nkp30 receptor targeted therapeutics |
MX2014003065A (es) | 2011-09-13 | 2015-05-11 | Deutsches Krebsforsch | Anticuerpo monoclonal terapeuticamente activo b7-h6 contra el polipeptido b7-h6. |
CN110511278A (zh) * | 2012-05-07 | 2019-11-29 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
EP2711707A1 (en) | 2012-09-21 | 2014-03-26 | Institut Gustave Roussy | Methods and kits for predicting the sensitivity of a subject to chemotherapy |
WO2014044799A1 (en) * | 2012-09-21 | 2014-03-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for the diagnosing of inflammatory conditions involving detecting, identifying or assaying for soluble b7-h6 polypeptides |
EP3442576A4 (en) * | 2016-04-15 | 2020-05-13 | Trustees of Dartmouth College | HIGH AFFINITY B7-H6 ANTIBODIES AND ANTIBODY FRAGMENTS |
US11191771B2 (en) * | 2016-06-09 | 2021-12-07 | Seagen Inc. | Combinations of PBD-based antibody drug conjugates with FLT3 inhibitors |
JP2021503503A (ja) * | 2017-11-16 | 2021-02-12 | アンティジェネシス・リミテッド・ライアビリティ・カンパニーAntigenesis LLC | リソソーム誘発性免疫原性細胞死のシステムおよび方法 |
JP2023510211A (ja) * | 2020-01-17 | 2023-03-13 | ベイジーン リミテッド | 抗NKp30抗体及び使用方法 |
AU2022246048A1 (en) | 2021-03-26 | 2023-08-31 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
CN114395044B (zh) * | 2021-12-07 | 2023-12-29 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
CN114395045B (zh) * | 2021-12-07 | 2023-06-09 | 合肥天港免疫药物有限公司 | B7h6抗体及其应用 |
CN114395043B (zh) * | 2021-12-07 | 2023-07-11 | 合肥天港免疫药物有限公司 | Ncr3lg1抗体及其应用 |
CN114634574B (zh) * | 2022-04-18 | 2022-12-20 | 先进生物(苏州)有限公司 | 抗B7H6的scFv抗体、其编码基因及其应用 |
KR20240003756A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | NKp30 결합력이 향상된 B7-H6 변이체 |
WO2024104777A1 (en) * | 2022-11-16 | 2024-05-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | T cell-nk cell interaction inhibitors for use in disease treatment |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4883662A (en) | 1984-04-10 | 1989-11-28 | Clinical Biotechnologies, Inc. | Method of increasing natural killer cell population of cancer patients |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5082833A (en) | 1988-06-30 | 1992-01-21 | Shamsuddin Abulkalam M | Reduction of cell proliferation and enhancement of nk-cell activity |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
JP3202999B2 (ja) | 1991-01-31 | 2001-08-27 | 協和醗酵工業株式会社 | 肝移行性リポソーム製剤 |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US5556623A (en) | 1993-03-30 | 1996-09-17 | Eli Lilly And Company | Antibody-drug conjugates |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
ES2195036T3 (es) | 1995-12-22 | 2003-12-01 | Bristol Myers Squibb Co | Conectores de hidrazona ramificados. |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
EP0973540B1 (en) | 1997-02-25 | 2005-11-02 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
WO2001051514A1 (en) * | 2000-01-07 | 2001-07-19 | Millennium Pharmaceuticals, Inc. | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
WO2004022594A2 (en) * | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
JP2008540569A (ja) * | 2005-05-12 | 2008-11-20 | ザイモジェネティクス, インコーポレイテッド | 免疫系を調整するためにB7ファミリーメンバーであるpNKp30を使用する方法 |
US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
ES2629440T5 (es) | 2007-10-04 | 2020-11-20 | Zymogenetics Inc | zB7H6 miembro de la familia B7 y composiciones y métodos relacionados |
MX2012006443A (es) | 2009-12-09 | 2012-06-28 | Inst Nat Sante Rech Med | Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos. |
-
2010
- 2010-12-08 MX MX2012006443A patent/MX2012006443A/es active IP Right Grant
- 2010-12-08 CA CA2783740A patent/CA2783740C/en active Active
- 2010-12-08 JP JP2012542637A patent/JP2013513380A/ja not_active Ceased
- 2010-12-08 PT PT108131160T patent/PT2510011E/pt unknown
- 2010-12-08 DK DK10813116.0T patent/DK2510011T3/en active
- 2010-12-08 EA EA201270654A patent/EA024629B1/ru not_active IP Right Cessation
- 2010-12-08 PL PL10813116T patent/PL2510011T3/pl unknown
- 2010-12-08 BR BR112012013975A patent/BR112012013975B8/pt active IP Right Grant
- 2010-12-08 ES ES10813116.0T patent/ES2523472T3/es active Active
- 2010-12-08 SI SI201030801T patent/SI2510011T1/sl unknown
- 2010-12-08 CN CN201510169548.3A patent/CN104926942B/zh active Active
- 2010-12-08 CN CN201080063065.0A patent/CN102741290B/zh active Active
- 2010-12-08 IN IN4908DEN2012 patent/IN2012DN04908A/en unknown
- 2010-12-08 RS RS20140657A patent/RS53667B1/en unknown
- 2010-12-08 US US13/515,276 patent/US8822652B2/en active Active
- 2010-12-08 EP EP10813116.0A patent/EP2510011B2/en active Active
- 2010-12-08 WO PCT/IB2010/003411 patent/WO2011070443A1/en active Application Filing
-
2014
- 2014-08-04 US US14/450,921 patent/US9663577B2/en active Active
- 2014-12-02 HR HRP20141170AT patent/HRP20141170T1/hr unknown
- 2014-12-11 SM SM201400184T patent/SMT201400184B/xx unknown
-
2016
- 2016-07-29 JP JP2016149287A patent/JP6212181B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EP2510011A1 (en) | 2012-10-17 |
CN104926942B (zh) | 2018-09-14 |
MX2012006443A (es) | 2012-06-28 |
US9663577B2 (en) | 2017-05-30 |
PT2510011E (pt) | 2014-12-12 |
CN102741290A (zh) | 2012-10-17 |
EP2510011B1 (en) | 2014-09-17 |
JP6212181B2 (ja) | 2017-10-11 |
DK2510011T3 (en) | 2014-12-01 |
US8822652B2 (en) | 2014-09-02 |
ES2523472T3 (es) | 2014-11-26 |
EA201270654A1 (ru) | 2013-02-28 |
BR112012013975B1 (pt) | 2021-01-12 |
PL2510011T3 (pl) | 2015-02-27 |
SMT201400184B (it) | 2015-01-15 |
JP2017031147A (ja) | 2017-02-09 |
US20130004432A1 (en) | 2013-01-03 |
BR112012013975B8 (pt) | 2021-05-25 |
CA2783740A1 (en) | 2011-06-16 |
WO2011070443A1 (en) | 2011-06-16 |
US20150056214A1 (en) | 2015-02-26 |
CA2783740C (en) | 2020-03-10 |
EP2510011B2 (en) | 2021-03-31 |
EA024629B1 (ru) | 2016-10-31 |
BR112012013975A2 (pt) | 2017-01-10 |
SI2510011T1 (sl) | 2014-12-31 |
CN102741290B (zh) | 2015-04-22 |
HRP20141170T1 (hr) | 2015-01-30 |
RS53667B1 (en) | 2015-04-30 |
CN104926942A (zh) | 2015-09-23 |
JP2013513380A (ja) | 2013-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN04908A (es) | ||
IL287292A (en) | and fusion antibody-drug-cd79b engineered antibodies cysteine- | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
EA201070463A1 (ru) | Комбинированная терапия с использованием конъюгатов антитело-лекарственное средство | |
NO20084356L (no) | Anti TAT226-antistoffer og immunokonjugater | |
PH12016500658B1 (en) | Human anti-alpha-synuclein autoantibodies | |
NZ595574A (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
MY170719A (en) | Antibody-drug conjugates | |
NZ602220A (en) | Antibodies with ph dependent antigen binding | |
CY1116261T1 (el) | Αντισωματα και ανοσοσυζευγματα και χρησεις αυτων | |
SG170091A1 (en) | Anti-5t4 antibodies and uses thereof | |
HK1162119A1 (en) | Animal models and therapeutic molecules | |
UA107574C2 (ru) | Гуманизированное антитело, специфическое к протофибрилярной формы бета-амилоидного пептида | |
WO2009046407A3 (en) | B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS | |
MY186725A (en) | Cross-linkers and their uses | |
IL214983A0 (en) | Antibody drug conjugated that bind monomethyl auristatin e (mmae), compositions comprisimg the same and uses thereof | |
MX2010007767A (es) | Anticuerpos manipulados con cisteina para conjugacion especifica de sitio. | |
AU2011343161A8 (en) | Human anti-SOD1 antibodies | |
MX2012009564A (es) | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. | |
NZ616382A (en) | Antibodies specific to cadherin-17 | |
MX2009005103A (es) | Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo. | |
EP2519542A4 (en) | ANTI-CDH3 ANTIBODY AND ITS USE | |
CY1116022T1 (el) | Μονοκλωνικα αντισωματα τα οποια δεσμευουν ton β7η6 και χρησεις αυτων | |
UA99211C2 (en) | Nanocapsules with functions of nanorobot |